Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixabepilone versus paclitaxel or doxorubicin in previously treated advanced endometrial cancer
2008-007167-16Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ixabepilone in endometrial cancer (EC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Overall survival. Started Jul 2009; status: completed.
02
Drugs
ixabepilone
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2008-007167-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007167-16.